

VGI Health Technology Limited – NAFLD/NASH Phase II Clinical Study Recruits First Patient

Sydney, New South Wales, 14 September 2022 – VGI Health Technology Limited is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (**Invictus**), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (**NAFLD**)/Non-Alcoholic SteatoHepatitis (**NASH**).

Research Governance Office approvals have been received from the Fiona Stanley Hospital in Western Australia, the Concord Repatriation General Hospital and the John Hunter Hospital in New South Wales and these sites have been added as clinical study sites along with the existing sites The Gallipoli Medical Research Foundation (**GMRF**) in Queensland and The Royal Melbourne Hospital in Victoria.

The study will enrol eighty **NAFLD/NASH** patients across eight sites in Australia and these five sites have commenced recruitment of patients.

This study will be a randomised, double-blind, placebo-controlled Phase II clinical study on **NAFLD/NASH** to analyse the efficacy and safety of IVB001, a drug candidate based on the non-invasive and direct delivery of tocotrienols using **Invictus**' patented transmucosal delivery platform.

Professor Darrell Crawford, the Director of Research for the **GMRF** and a Member of the **Invictus** Scientific Advisory Board, said "We are very excited that the first patient for this Phase II clinical study in **NAFLD/NASH** has now been recruited and this patient is expected to commence dosing on 5 October 2022."

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp